Evidence map›Paper›PMID 41608626›Full record

ArticleInternational journal of biological sciences2026

Loss of UFL1 confers enzalutamide resistance of prostate tumors by regulating METTL16-mediated m6A modification of EEF1A1 mRNA.

Xu Wu, Hui Gao, Qianfeng Zhuang, Feng Li, Xingliang Feng, Naiyuan Shao, Wei Zhang, Yuyang Zhang, Xiansheng Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xu WuDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Hui GaoDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Qianfeng ZhuangDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China.
Feng LiDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Xingliang FengDepartment of Urology, The Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu, China.
Naiyuan ShaoDepartment of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Wei ZhangDepartment of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China.
Yuyang ZhangReproductive Medicine Center, Department of Obstetrics and Gynecology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Xiansheng ZhangDepartment of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enzalutamide (ENZ), a next-generation androgen receptor (AR) inhibitor, is a cornerstone treatment for metastatic prostate cancer. However, resistance to ENZ inevitably develops in these patients, and the mechanisms underlying this resistance remain poorly understood. This study reveals that UFL1 is dysregulated in ENZ-resistant cells, xenograft models, and prostate tumors. UFL1 deficiency enhances prostate cancer cell resistance to ENZ both

Indexed as

BenzamidesDrug Resistance, NeoplasmMethyltransferasesNitrilesPeptide Elongation Factor 1PhenylthiohydantoinProstatic NeoplasmsAnimalsApoptosisCell Line, TumorHumansMaleMiceRNA-Binding ProteinsRNA, MessengerRNA MethylationBenzamidesEEF1A1 protein, humanenzalutamideMethyltransferasesNitrilesPeptide Elongation Factor 1PhenylthiohydantoinRNA-Binding ProteinsRNA, MessengerEEF1A1enzalutamide resistanceMETTL16UFL1

Identifiers

PMID41608626
PMCPMC12837662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.